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Abstract: Cancer is the leading cause of disease-related death in companion animals such 
as dogs and cats. Despite recent progress in the diagnosis and treatment of advanced canine 
and feline cancer, overall patient treatment outcome has not been substantially improved. 
Virotherapy using oncolytic viruses is one promising new strategy for cancer therapy. 
Oncolytic viruses (OVs) preferentially infect and lyse cancer cells, without causing 
excessive damage to surrounding healthy tissue, and initiate tumor-specific immunity. The 
current review describes the use of different oncolytic viruses for cancer therapy and their 
application to canine and feline cancer. 
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1. Introduction 
Cancer is among the top fatal diseases in domestic and feral dogs and cats [1–5]. Incidence of 
canine or feline cancer ranges from 1% to 2% and cancer currently accounts for about half of the 
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deaths of domestic animals older than 10 years [1,6,7]. The most common forms of cancer in dogs and 
cats are skin, lymphoma, mammary, bone, connective tissue, and oral cancers [1,7]. The traditional and 
established methods for pet cancer treatment include surgery, radiation therapy, chemotherapy, 
hyperthermia and photodynamic therapy. However, the available treatment options for pet patients 
with advanced-stage disease are limited and the prognosis for such patients is very poor. Therefore, 
developing novel therapies, which may also work synergistically in combination with the conventional 
treatment options, is crucial.  
One promising new therapeutic approach is oncolytic virotherapy. Oncolytic viruses (OVs) exhibit 
selective viral replication in tumors and metastases resulting in the killing of cancer cells and the 
initiation of tumor-specific immunity [8,9]. Several OVs including adenovirus, herpes simplex virus, 
vaccinia virus, Seneca Valley virus and reovirus are currently in human clinical trials, the most 
advanced of which is in Phase III [10,11]. In addition, in China, the oncolytic adenovirus H101 has 
been approved for combination therapy of human cancer patients [12].  
In contrast to the progress of human oncolytic virotherapy, there are very few clinical trials using 
OVs for canine or feline cancer patients [13,14]. Since many forms of canine or feline neoplasms 
resemble their human counterparts in histological appearance, tumor genetics, biologic behavior, 
pathologic expression, recognized risk factors and response to therapy [15–18], it is reasonable to 
expect that the human clinical protocols will transfer directly to the treatment of pet cancer patients. 
There are strong similarities between naturally occurring human and canine cancers including 
colorectal carcinoma, fibrosarcoma, osteosarcoma, soft tissue sarcoma, Non-Hodgkin and Burkitt 
lymphomas and small lymphocytic lymphoma [19]. Several types of feline neoplasms such as 
squamous cell carcinoma and mammary carcinoma also show similarities in tumor biology, expression 
patterns and prognosis with human head and neck squamous cell carcinoma and a wide subset of 
human breast cancers [20,21]. As OVs show continuous promise in clinical application for treatment 
of many cancer types in human patients and considering the high similarity and increasing frequency 
of these cancers in pets, we believe that oncolytic virotherapy could soon be a reality also in veterinary 
medicine. Moreover the data from canine studies are more reliable and may be helpful in designing 
human clinical trials. The translation of oncolytic virotherapy from dogs to humans and the reverse 
could be a two-way street for development of drugs. 
This review describes the most common classes of OVs and their progress in preclinical studies 
with canine and feline cancers. Presented are also the challenges and the major obstacles to the optimal 
practice of oncolytic virotherapy in pet cancer patients.  
2. Oncolytic Virotherapy for Canine and Feline Cancers 
Many wild type or recombinant viruses have been tested as oncolytic agents for treatment of canine 
or feline cancer. They include human and canine adenoviruses, canine distemper virus (CDV), reovirus 
and members of the poxvirus family such as vaccinia virus, recombinant canary poxvirus (ALVAC), 
NYVAC (derived from the Copenhagen vaccinia strain) and myxoma virus.  
  




Adenoviruses have been widely characterized for oncolytic therapy in humans, but beyond this they 
have the ability to infect a broad range of cell types across many species [22,23]. For this reason, 
human and canine adenoviruses have been used as therapeutic agents for canine and feline cancers 
(Table 1). For example, human adenovirus 5 (Ad5) productively replicates in canine osteosarcoma, 
canine melanoma and canine mammary carcinoma cells [24,25]. Several Ad5-based adenoviral vectors 
expressing different genetic or molecular factors associated with cancer such as p53, CD40 ligand or 
feline IL-12 have been tested with success for treatment of different canine and feline tumors [26–28].  
Table 1. Oncolytic viruses tested for canine and/or feline cancer therapy.  
Virus strain Virus family/Virus type Study/Tumor type/Animal model Ref. 
Canine adenovirus type 2 (CAV2) 
Adenoviridae (double 
stranded DNA viruses) 
Infection of canine osteosarcoma cells and 
osteosarcoma xenografted mice 
[29] 
Human adenovirus type 5 (Ad5) Adenoviridae 
Infection of canine osteosarcoma, melanoma and 
mammary carcinoma cells 
[24] 
Ad5, CAV2 Adenoviridae 








Treatment of canine osteosarcoma xenografts 
using tumor cells as a carrier for CAV2 
[31] 
Ad5-based vector with CD40 ligand (AdCD40L) Adenoviridae Treatment of canine malignant melanoma patients [32,33] 
Ad5-based vector encoding IL-12 (Ad hsp feline 
IL-12) 
Adenoviridae Treatment of cats with soft tissue sarcoma [28] 
Ad5-vector-mediated p53 gene transfer Adenoviridae Treatment of canine osteosarcoma xenografts [26] 
Canine Distemper Virus (CDV) 
Paramyxoviridae (single 
stranded RNA viruses) 
Infection of canine lymphoid, osteosarcoma and 




stranded RNA viruses) 
Infection of canine mast cell tumor cells (MCT) 
and treatment of MCT xenograft mice 
[35] 
Vaccinia virus (Lister) strain (GLV-1h68)  
Poxviridae (double 
stranded DNA viruses) 
Treatment of canine mammary adenoma and 
carcinoma and soft tissue sarcoma xenograft mice 
[36–38] 
Vaccinia virus (Lister) strain expressing  
anti-VEGF antibody (GLV-1h109) 
Poxviridae 
Treatment of canine soft tissue sarcoma and 
prostate xenograft mice 
[39] 
Vaccinia virus (Lister) strain (LIVP 6.1.1) Poxviridae 
Treatment of canine soft tissue sarcoma and 
prostate xenografted mice 
[40] 
Vaccinia virus (Lister) strain expressing  
anti-VEGF antibody (GLV-5b451) 
Poxviridae 
Treatment of feline mammary carcinoma 
xenograft mice 
[41] 
Myxoma virus (MYXV) Poxviridae Infection of different canine tumor cells [42] 
Myxoma virus (MYXV) Poxviridae Infection of feline carcinoma cells [43] 
Canary pox virus expressing IL2 (ALVAC-fIL2)  Poxviridae Therapy of cats with feline fibrosarcomas  [14] 
Vaccinia virus (Copenhagen) strain expressing 
IL2 (NYVAC-fIL2) 
Poxviridae Therapy of feline fibrosarcoma patients [14] 
Abbreviations: Ad5—Human adenovirus type 5; CAV2—Canine adenovirus type 2; IL2—interleukin 2;  
IL-12—interleukin 12; fIL2—feline interleukin 2; VEGF—Vascular endothelial growth factor.  




However, the level of human adenovirus replication in canine cells is about 2 logs lower than in 
human cells [24]. On the other hand, canine adenovirus, while not as well studied, displays 
significantly improved viral replication in canine cancer cells. The conditionally replicating canine 
adenovirus 2 (CAV2) with the osteocalcin promoter showed replication in canine osteosarcoma cells 
only [30] and a significant therapeutic effect in canine osteosarcoma xenografts [29,31]. In addition, 
administration of this modified canine adenovirus to normal dogs showed only moderate virus-associated 
toxicity [30]. However, clinical use of CAV2 and its vectors can, under some conditions, be limited by 
pre-existing vector immunity [44]. Therefore, strategies to overcome the pre-existing humoral and 
cellular adenovirus specific immunity in dogs should be developed (see Section 3.2). 
The introduction and expression of heterologous genes by adenoviruses can lead to enhanced 
therapeutic activity. For example, the adenoviral vector, AdCD40L, expressing a CD40 ligand exhibited 
complete tumor regression in 5 of 19 canine melanoma patients after intratumoral injection [32]. The 
results suggest that AdCD40L therapy is safe as administered and could have beneficial effects in 
treatment of canine melanoma. 
2.2. Morbilliviruses 
Canine distemper virus (CDV) is an enveloped virus with a single stranded RNA genome belonging 
to the genus morbillivirus of the paramyxoviridae family. It is a close relative of measles virus (MV). 
In fact, both MV and CDV use a similar cellular receptor for entry into cells [45]. Historically, children 
with Hodgkin’s disease were observed to experience regression after concurrent MV infection [46]. 
These observations prompted the consideration of attenuated MV for the treatment of human 
lymphoma and, consequently, measles virus has shown promising anti-tumor activity against a variety 
of malignant neoplasms in both preclinical and clinical studies [47]. Because of its similarity to MV, 
CDV was considered for treatment of canine lymphoma. CDV binds to the cellular receptor, the 
signaling lymphocyte activation molecule (SLAM or CD150) [48], which is over-expressed on 
malignant canine B and T lymphocytes [34]. Attenuated CDV was able to infect canine lymphoma 
cells in cell culture via binding to CD150 and to induce apoptosis in these cells [34]. While 
preliminary, these results support the continued evaluation of CDV for the treatment of canine 
lymphoma. 
Nevertheless, the most dogs are vaccinated against canine distemper virus and the high prevalence 
of virus-neutralizing antibodies is one major obstacle to the use of CDV in canine clinical trials. The 
use of vectors of non-canine origin like e.g., MV or removing key neutralizing epitopes on the surface 
of viral capsid proteins might help to avoid pre-existing immunity. In addition, intratumoral or 
mucosal virus application or administration of higher virus doses could also be a solution for  
pre-existing immunity problems (for general review see [49]). 
 
2.3. Reovirus 
Reovirus, a non-enveloped icosahedral virus with segmented double stranded RNA, has been 
extensively tested in oncolytic virotherapy of human cancers over the past decade. While its clinical 
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development has advanced into phase II and III clinical trials with human cancer patients, it has been 
hardly studied as a canine or feline oncolytic agent. A very recent study demonstrated for the first time 
that canine mast cell tumors (MCT) were highly susceptible to reovirus infection in vitro [35]. In 
addition, a single intratumoral reovirus injection significantly regressed canine mast cell tumor 
xenografts [35]. However, reovirus also infected normal canine mast cells raising safety concerns. 
Subsequent studies should address these concerns before using reovirus as an oncolytic agent for 
canine cancer therapy. 
2.4. Poxviruses 
Several preclinical and clinical studies with vaccinia virus (VACV) strains have demonstrated 
promising oncolytic properties [50]. VACV is a double stranded DNA virus of the poxvirus  
family [51,52]. Since it was the first widely used vaccine (in over 200 million people), resulting in 
worldwide eradication of smallpox, much is known about its safety profile [53]. Three different 
oncolytic vaccinia virus strains, GL-ONC1/GLV-1h68, V-VET-1/LIVP 6.1.1 (Genelux Corporation, 
San Diego, CA, USA) and JX-594 (Jennerex Biotherapeutics, Inc., San Francisco, CA, USA) are now 
undergoing clinical trials with either human or canine cancer patients [40,54,55]. The JX-594 construct 
was derived from the Wyeth strain by deletion of the thymidine kinase (tk) gene via insertion of GM-
CSF and lacZ genes [56]. LIVP 6.1.1 was isolated from a wild type stock of Lister strain of vaccinia 
virus (Lister strain, Institute of Viral Preparations (LIVP), Moscow, Russia) and represents a “native” 
virus (no genetic manipulations were conducted). Interestingly, the thymidine kinase (tk) gene of LIVP 
6.1.1 virus is inactive [57]. Several groups have reported that TK-mutant vaccinia viruses are 
significantly attenuated and demonstrate enhanced tumor-specific replication in vivo [54,58]. GLV-1h68 
(named GL-ONC1 as produced for clinical investigation) was developed from the Lister strain by 
inserting three expression cassettes encoding Renilla luciferase–Aequorea green fluorescent protein 
fusion (Ruc-GFP), LacZ, and β-glucuronidase into the F14.5L, J2R (thymidine kinase) and A56R 
(hemagglutinin) loci of the viral genome, respectively [54].  
GLV-1h68 has been tested with success in the treatment of canine mammary adenoma, mammary 
carcinoma and soft tissue sarcoma in xenograft tumor models [36–38]. In all three models, significant 
inhibition of tumor growth was observed after a single systemic administration of GLV-1h68 [36–38]. 
Additionally, GLV-1h68 enabled the detection of metastases via optical imaging [59,60]. GLV-1h109, 
a variant of GLV-1h68, expressing the anti-VEGF (Vascular Endothelial Growth Factor) single chain 
antibody (scAb) GLAF-1, demonstrated strong antitumor effects in canine soft tissue sarcoma and 
prostate carcinoma xenograft models [39]. Localization of GLV-1h109 and expression of GLAF-1 in 
the tumor tissue inhibited tumor angiogenesis. Similar data was obtained by the use of the new 
recombinant oncolytic vaccinia virus strain GLV-5b451, a variant of LIVP 6.1.1, expressing GLAF-2, 
in a feline mammary carcinoma xenograft model [41]. GLAF-1 and GLAF-2 single chain antibodies 
are identical with exception that GLAF-1 contains a FLAG-tag for purification purposes [61].  
The oncolytic effect of LIVP 6.1.1 was studied in a panel of four different canine cancer cell lines 
including soft tissue sarcoma STSA-1, melanoma CHAS, osteosarcoma D17 and prostate carcinoma 
DT08/40 cells [40]. LIVP 6.1.1 was shown to efficiently infect, replicate in and lyse all tested canine 
cancer cells in culture [40]. In addition, two subclones of LIVP, LIVP 6.1.1 and LIVP 1.1.1, have 
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shown great promise in the treatment of STSA-1 and/or DT08/40 tumor xenografts [38,40]. 
Interestingly, DNA sequence analysis of LIVP 1.1.1 revealed that the thymidine kinase (tk) gene of 
this strain is also inactive [57]. 
A phase I clinical study is underway to evaluate the safety of intravenous administration of LIVP 
6.1.1 for treatment of canine cancer patients at Angel Care Cancer Center, Carlsbad, CA, USA.  
Oncolytic activity of several other poxviruses, such as ALVAC, NYVAC and myxoma virus, has 
been evaluated in canine and feline tumors. Despite the fact that myxoma virus (MYXV) replicates 
only in lagomorphs and is only pathogenic in the European rabbit, it has shown efficient infection in 
human cancer cell types. Constant activation of cellular transformation pathways and the inability of 
tumor cells to elicit antiviral immune response helps MYXV to replicate in human cancer cells [62,63]. 
Moreover, MYXV can infect and lyse various canine and feline tumor cells in vitro [42,43]. Further 
studies of myxoma virus as an oncolytic agent in vivo are needed to determine its potential in treating 
dog and cat cancers. 
ALVAC-fIL2 and NYVAC-fIL2 are recombinant, non-replicating canary poxvirus and highly 
attenuated vaccinia virus, respectively, encoding the feline IL2 gene [14]. When combined with 
surgery and radiotherapy, treatment with either of these viruses prevented feline fibrosarcoma recurrence 
in cats [14].  
2.5. What Could Be the Possible Mechanisms of Oncolytic Virus Mediated Tumor Ablation?  
An oncolytic virus destroys tumors either by direct viral lysis of tumor cells [64,65], by destruction 
of the tumor vasculature [66], by induction of host antitumoral immune responses [67–69], or most 
likely, a combination of these mechanisms [11,70] (Figure 1). An increased infiltration of neutrophils, 
macrophages and natural killer (NK) cells to the tumor site might be involved in the VACV-mediated 
immune response in different canine cancer xenograft models [37,38,40]. The presence of such 
activated inflammatory cells in the tumor tissue may enhance the antitumoral effect by increasing the 
phagocytic or cytotoxic activities of these cells [71,72]. In addition, an increase in proinflammatory 
interferon-gamma (IFN-gamma), interleukin-2 (IL-2), interleukin-6 (IL-6), tumor necrosis factor alpha 
(TNF-alpha), interferon gamma-induced protein 10 (IP-10), macrophage inflammatory protein-1 alpha 
(MIP-1 alpha), macrophage inflammatory protein-1 beta (MIP-1 beta), monocyte chemotactic  
protein-1 (MCP-1), and monocyte chemotactic protein-3 (MCP-3) was observed in vaccinia virus 
infected canine xenografted mice [37,38]. Many of these proteins stimulate innate immunity mediated 
by dendritic cells, neutrophils, macrophages and NK cells.  
OVs naturally prevent neoangiogenesis either by direct infection and destruction of tumor 
vasculature [66] or “vascular normalization” in tumor tissue, as described by Winker and colleagues [73]. 
Moreover, oncolytic viruses can be additionally armed to enhance their natural antiangiogenic ability. 
VEGF is a key regulator of tumor angiogenesis and several anti-VEGF strategies have been developed 
for the treatment of different cancers [74–76]. Vaccinia virus expressing anti-VEGF antibodies 
significantly decreased neoangiogenesis at the tumor site and inhibited tumor growth in canine and 
feline xenografts [39,41]. Thus, strategies employing virus-encoded and delivered anti-VEGF 
antibodies in combination with OV may be effective therapeutic approaches for pet cancer patients. 
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At the present there are not enough data from pet cancer patients treated with oncolytic viruses to 
allow an understanding of OV-mediated tumor ablation. However, it is expected that factors such as 
origin of tumor, stage of tumor development and combination therapy, and, importantly, the balance 
between antiviral and antitumoral immune responses will play a role. 
Figure 1. Possible mechanisms of oncolytic virus mediated tumor ablation. 
 
Abbreviations: MФ: macrophages; NK: natural killer cells; DC: dendritic cells; Neutr.: neutrophils;  
IFN-gamma: interferon-gamma; IL-2: interleukin-2: IL-6: interleukin-6; TNF-alpha: tumor necrosis factor 
alpha: IP-10: interferon gamma-induced protein 10; MIP-1 alpha: macrophage inflammatory protein-1; MCP-1: 
monocyte chemotactic protein-1; MCP-3: monocyte chemotactic protein-3; TAA: tumor-associated antigens. 
3. Open Questions Regarding the Use of Oncolytic Virotherapy in Veterinary Medicine 
The major obstacles that restrict the optimal use of oncolytic viruses as therapeutics for canine or 
feline cancer patients are viral toxicity, ineffective delivery of virus to tumor and inefficient spread of 
OVs throughout the tumor mass.  
3.1. Toxicity of Oncolytic Viruses to Pet Cancer Patients 
As for all experimental therapeutic agents and treatments, a primary concern of virotherapy is 
toxicity. Treatment-related toxicity is common for chemotherapy and radiation therapy in canine or 
feline cancers [77–79]. While only a few clinical trials of oncolytic virotherapy in canine or feline 
cancer patients have been carried out, evidence for the lack of toxicity of OVs in pets is emerging. 
Intravenous administration of canine adenovirus-2 in normal dogs and AdCD40L (adenovector 
expressing the CD40 ligand) in canine malignant melanoma cases did not show any virus associated 
toxicity [30,80]. In a very recently completed phase I study, Westberg and colleagues reported that 
AdCD40L therapy in canine melanoma patients was safe and only mild adverse effects were 
associated with treatment [32]. Sufficient evidence of oncolytic viruses as a safe therapeutic modality 
is displayed by several studies [33,81,82]. Furthermore, genetic engineering of oncolytic viruses is 
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supported by the safety data from genetically engineered products like DNA vaccine in dogs and  
non-human primates [83–85]. Overall both wild type and genetically engineered oncolytic virus 
therapy appears to be as safe as standard anti cancer therapies.  
3.2. Optimization of OV Delivery to the Tumor Tissue and Metastases  
Immune responses against therapeutic viruses may presumably hamper ongoing viral replication in 
immunocompetent dogs and cats. Several factors including neutralizing antibodies, inactivation by 
complement and sequestration in the liver and spleen could impair the effectiveness of the virus 
especially after intravenous virus application, the preferred route of administration for treatment of 
metastatic cancer. One of the most promising strategies to evade virus inactivation by these factors is 
carrier-based delivery. Several types of cells, such as immune cells [86], stem cells [87] and tumor 
cells [88] have been successfully utilized as carriers of OVs to the tumor.  
Canine osteosarcoma cells treated with replication selective canine adenovirus (OCCAV) were used 
as virus carriers for evading pre-existing neutralizing antibodies against adenovirus. When 
administered systemically, even in the presence of adenovirus neutralizing antibodies, OCCAV carrier 
cells showed superior infection of tumors and tumor regression in a xenograft mouse model compared 
to OCCAV alone [31]. Moreover, the enhanced oncolytic effects were attributed to an increase in the 
effective local viral dose in the tumor as a consequence of the tumor-specific delivery of the virus by 
the cells and the escape of the pre-existing antiviral immunity [88,89].  
In addition, virus coatings with biocompatible polymers such as polyethylene glycol (PEG) [90], 
silk-elastinlike protein [91] or N-[2-hydroxypropyl]meth-acrylamide (HPMA) [92] or with serum 
proteins [93,94] showed a minimized sequestration by the mononuclear phagocytic system in the liver 
and spleen. Furthermore, delivery of viruses within injectable polymer matrices has been shown to 
enhance antitumor effects compared to virus alone. Intratumoral injection of an adenovirus vector into 
human head and neck cancer xenograft tumors in a silk-elastinlike protein hydrogel increased the 
stability of the virus and the duration of its release into the tumor microenvironment [67]. 
In general, carrier-mediated deliveries of OVs may increase the efficiency of viral tumor colonization 
and protect the virus against the components of the host innate or acquired immune system.  
3.3. Enhancing Viral Spread throughout the Tumor 
The improvement of virus spread in tumor tissue is an important challenge for effective oncolytic 
virotherapy [95]. The tumor extracellular matrix (ECM) or stroma presents a substantial physical 
barrier to virus spread. Structural components of tumor ECM, such as collagens and proteoglycans, 
have been shown to hinder distribution of large therapeutic molecules and viruses [96]. Several groups 
have reported that the intratumoral spread and efficacy of OVs was improved by protease or 
hyaluronidase-mediated digestion of tumor ECM [97–99]. While preliminary, these results suggest that 
such strategies may be clinically useful.  
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3.4. Biosafety of Treatment 
Oncolytic viruses also raise new biosafety and risk management issues [100,101]. The risk 
assessment for trials with these agents must take into account and mitigate the potential risk of 
transmission of the infectious agent to other pets and persons in contact with the treated patient. The 
zoonotic aspects or risk to pet owners and general public has to be monitored. The spectrum of 
diseases caused by parental viral strains in dogs or cats is an important safety factor for consideration. 
If necessary, the risk of disease or adverse effects from a viral therapeutic could be countered with 
antiviral agents effective against the viral strains considered for cancer treatment.  
4. Conclusions  
The significant incidence and mortality associated with canine and feline cancers continues to 
challenge modern veterinary medicine to develop more reliable therapies. One of the most promising 
novel cancer therapies is oncolytic virotherapy. This method is based on the capability of OVs to 
preferentially infect and lyse cancer cells and to initiate tumor-specific immunity. Several oncolytic 
viruses including human and canine adenoviruses, canine distemper virus (CDV), reovirus and 
vaccinia virus strains have been tested with convincing results in preclinical studies.  
As for oncolytic virotherapy of human cancers, the most important challenges for the successful 
clinical use of OVs in veterinary practice are reduction of viral toxicity, optimization of virus delivery 
to tumor, and enhancement of viral spread throughout the tumor mass.  
Recently, the first clinical studies with vaccinia and adenovirus for canine cancer therapy are 
underway and we look forward to the forthcoming demonstrations of clinical utility. 
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